The abstract is read at the publisher; the summary is JClub's.
Circulating endotrophin levels are higher in estrogen receptor-positive, HER2-negative breast cancer than in triple-negative disease, with median 35.98 vs 19.67 ng/mL.
- Why it matters: Fibroinflammatory soluble factors are emerging as biomarkers, but endotrophin’s subtype specificity and whether blood levels predict treatment response were unclear.
- What they did: The study measured circulating endotrophin in 191 samples from 98 breast cancer patients, plus ovarian neoplasia (n=29) and healthy controls (n=19), and analyzed associations with treatment response in early-stage versus metastatic settings.
- The result: Endotrophin was linked to treatment response only in the metastatic setting, and it was detected in tumor and adjacent benign tissues, supporting further work on endotrophin as a biomarker in ER+ metastatic breast cancer.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.